Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc

16 Jan 2017

Abstract excerpt

In 2015, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Kandela et al., 2015) that described how we intended to replicate selected experiments from the paper "BET bromodomain inhibition as a therapeutic strategy to target c-Myc" (Delmore et al., 2011). Here we report the results of those experiments. We found that treatment of human multiple myeloma (MM) cells with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28100400
DOI: 10.7554/elife.21253

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-MycPMID 28100400Read ↗

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-MycSemantic proximity Read ↗

Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in miceSemantic proximity Read ↗

Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancerSemantic proximity Read ↗

Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell LymphomaSemantic proximity Read ↗

The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination StrategiesSemantic proximity Read ↗

Bromodomain Drug Discovery – the Past, the Present, and the FutureSemantic proximity Read ↗

Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of ProteinsSemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

Targeting BET bromodomain proteins in cancer: The example of lymphomasSemantic proximity Read ↗

Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cellsSemantic proximity Read ↗

The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft modelsSemantic proximity Read ↗

GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) ProteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.